We pioneer non-invasive stool tests, leveraging patient transcriptome & an AI-driven classifier, for advanced transcriptomics and precise diagnostics of IBD

Congratulations FreezeM, A spinoff company of Yeda, on securing a $14.2 Million series A round!

Your innovative 'breeding-as-a-service' model is set to revolutionize the insect farming industry, decoupling BSF breeding from rearing and processing makes protein production more efficient and simpler to scale. A big shoutout to Yuval Gilad and the entire FreezeM team for this tremendous milestone achievement. Looking forward to witnessing the positive impact on BSF farming and waste management with this cutting-edge approach!

The patent world is continuously evolving. Changes in international intellectual property laws and court rulings over the last two decades challenge the ability to protect inventive concepts, particularly in biotechnology. Despite the challenges, the global demand for patents consistently grows, creating a crowded patent environment.

A technology transfer company affiliated with the Weizmann Institute of Science has been engaged in the commercialization of scientific developments since 1959. "We helped bring dozens of startups and a variety of life-saving drugs to the world," says Dr. Opher Shapira, who heads the company and is responsible for the transition of scientific ideas into business enterprises

SLAM BioTherapeutics, a promising biotechnology company, dedicated to novel oncology and autoimmune therapies, announces a seed round of over $8 Million to advance its portfolio of antibodies. The company’s suite of antibodies targets a novel cell surface receptor expressed in the tumor microenvironment.

Leading the investment was Schwartz Capital Group. The funds raised will support SLAM Bio’s pre-clinical development efforts and facilitate Investigational New Drug (IND) enabling studies for its lead asset.

Yeda has been involved in the commercialization of scientific developments since 1959. "We have helped bring dozens of start-up companies and a variety of life-saving drugs to the world," says Dr. Opher Shapira, who heads the company and is responsible for the transition between a scientific idea and a business company

Yeda is excited to share more news originating from Curesponse, a commercial stage precision oncology company, which developed the cResponse™ platform, a functional-genomics oncology drug prioritization technology, that enables the precise determination of optimal drug treatments for individual cancer patients.

Curesponse is a spinoff company of Yeda.

This time Curesponse collaborated with Prof. Talia Golan, Head of the Pancreatic Cancer Center at Sheba medical hospital, which is ranked one of the top 10 hospitals in the world by Newsweek.

Yeda is thrilled to share news originating from Curesponse, which has developed a technology that enables the precise determination of optimal drug treatments for individual cancer patients.

This ground-breaking technology facilitates the analysis of samples extracted from cancerous tumors, providing oncologists with the means to assess the efficacy of different drugs on the patient's specific tumor.